LeMaitre Vascular (NASDAQ:LMAT) Issues Q3 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its third quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.660-0.710 for the period, compared to the consensus estimate of 0.730. The company issued revenue guidance of $66.3 million-$68.3 million, compared to the consensus revenue estimate of $69.0 million. LeMaitre Vascular also updated its FY 2026 guidance to 2.840-2.940 EPS.

LeMaitre Vascular Price Performance

NASDAQ:LMAT traded down $24.55 during trading hours on Wednesday, reaching $81.23. 915,357 shares of the company traded hands, compared to its average volume of 259,101. LeMaitre Vascular has a 1-year low of $79.39 and a 1-year high of $118.01. The stock has a market cap of $1.86 billion, a P/E ratio of 30.03, a P/E/G ratio of 2.88 and a beta of 0.53. The firm’s 50-day moving average is $97.41 and its 200-day moving average is $100.04. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 12.20.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by ($0.07). The company had revenue of $70.38 million during the quarter, compared to analysts’ expectations of $71.47 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The firm’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.60 earnings per share. Equities research analysts expect that LeMaitre Vascular will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be given a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Thursday, August 20th. LeMaitre Vascular’s payout ratio is currently 36.90%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LMAT. Citizens Jmp upped their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday. Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Wells Fargo & Company lowered their price objective on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating for the company in a research report on Wednesday. Finally, Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $110.60.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,881 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the completion of the transaction, the chief executive officer owned 1,430,019 shares in the company, valued at $155,428,765.11. This represents a 1.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Trent G. Kamke sold 2,928 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $107.00, for a total transaction of $313,296.00. Following the sale, the insider owned 3,749 shares in the company, valued at $401,143. This represents a 43.85% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 54,453 shares of company stock worth $5,906,174. Corporate insiders own 7.40% of the company’s stock.

Key LeMaitre Vascular News

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Second-quarter revenue increased 9.6% year over year to $70.38 million, while earnings per share rose to $0.74 from $0.60 a year earlier. The company also maintained strong profitability, with a 24.35% net margin. LeMaitre Q2 2026 Financial Results
• Positive Sentiment: LeMaitre declared a quarterly dividend of $0.25 per share, payable September 3 to shareholders of record August 20. The dividend represents an annualized yield of approximately 1.1%.
• Neutral Sentiment: Wells Fargo lowered its price target from $104 to $94 and maintained an “equal weight” rating, implying potential upside from the recent trading level but signaling a more cautious valuation view. Benzinga
• Negative Sentiment: Q2 EPS of $0.74 missed the $0.81 consensus estimate, while revenue of $70.38 million fell short of the $71.47 million forecast. LeMaitre Q2 Earnings and Revenues Lag Estimates
• Negative Sentiment: Management’s updated third-quarter guidance is below consensus: EPS of $0.66–$0.71 versus $0.73 expected and revenue of $66.3–$68.3 million versus $69.0 million expected.
• Negative Sentiment: Full-year 2026 guidance was also reduced to EPS of $2.84–$2.94 and revenue of $274.3–$278.3 million, below consensus estimates of $3.00 and $279.9 million, respectively.
• Negative Sentiment: Barrington Research downgraded LMAT from “outperform” to “market perform,” adding to the cautious investor reaction. Finviz

Institutional Trading of LeMaitre Vascular

Several large investors have recently modified their holdings of LMAT. Illinois Municipal Retirement Fund boosted its holdings in LeMaitre Vascular by 1.1% in the fourth quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock valued at $906,000 after purchasing an additional 123 shares during the last quarter. NewEdge Advisors LLC raised its position in shares of LeMaitre Vascular by 4.6% in the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after purchasing an additional 139 shares in the last quarter. Federated Hermes Inc. boosted its stake in shares of LeMaitre Vascular by 0.4% during the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock valued at $3,294,000 after buying an additional 155 shares during the last quarter. Equitable Holdings Inc. grew its position in shares of LeMaitre Vascular by 1.4% during the fourth quarter. Equitable Holdings Inc. now owns 14,469 shares of the medical instruments supplier’s stock worth $1,173,000 after buying an additional 205 shares in the last quarter. Finally, California State Teachers Retirement System grew its position in shares of LeMaitre Vascular by 1.7% during the second quarter. California State Teachers Retirement System now owns 18,721 shares of the medical instruments supplier’s stock worth $1,555,000 after buying an additional 316 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.